Leading Biotechnology made in Germany
Modern Array Technologies - SeraSpot®
Chemiluminescent Substrates
In-vitro tests for Quality Control analysis
Research & Development of Laboratory Diagnostics

Seramun Diagnostica GmbH

Our Vision

As a leading developer and manufacturer in vitro diagnostics and reagents for enzyme immunoassays especially of ready-to-use substrates, Seramun Diagnostica GmbH is your partner when it comes to meet special requirements, ensuring highest-level precision, keeping development times short and maintaining quality-controlled products in continual availability.

It is the company's vision that all key substances for the immunoassays which we offer are developed in-house and produced according to standardized procedures.

By cultivating close contacts with our customers and cooperating closely with scientific institutions, Seramun Diagnostica GmbH is able to realize a program of product maintenance and development that is oriented towards the very latest scientific developments.

Seramun News

𝗠𝗲𝗲𝘁 𝗦𝗲𝗿𝗮𝗺𝘂𝗻 𝗗𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰𝗮 𝗮𝘁 𝗠𝗘𝗗𝗜𝗖𝗔 𝟮𝟬𝟮𝟲

We are excited to announce that 𝗦𝗲𝗿𝗮𝗺𝘂𝗻 𝗗𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰𝗮 𝗚𝗺𝗯𝗛 will be exhibiting at 𝗠𝗘𝗗𝗜𝗖𝗔 𝟮𝟬𝟮𝟲, the world's leading medical trade fair, taking place from 16-19 November 2026 in Düsseldorf, Germany.

As part of the 𝗗𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰 𝗡𝗲𝘁𝘄𝗼𝗿𝗸 𝗕𝗲𝗿𝗹𝗶𝗻-𝗕𝗿𝗮𝗻𝗱𝗲𝗻𝗯𝘂𝗿𝗴, you can find us in 𝗛𝗮𝗹𝗹 𝟯, 𝗕𝗼𝗼𝘁𝗵 𝗖𝟳𝟮-𝟰.

MEDICA brings together healthcare professionals, laboratory experts, distributors, and industry leaders from around the globe, creating a unique platform for innovation, networking, and business development.

Seramun Diagnostica attending ETBD 2026 in Rumania (12 - 13 November, 2026)

𝗙𝗲𝗮𝘁𝘂𝗿𝗲𝗱 𝗮𝘁 𝗘𝗧𝗕𝗗 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 𝟮𝟬𝟮𝟲:

Reliable and accurate diagnosis is essential for the effective management of Lyme borreliosis. That's why we are proud to showcase our 𝗦𝗲𝗿𝗮𝗦𝗽𝗼𝘁® 𝗔𝗻𝘁𝗶-𝗕𝗼𝗿𝗿𝗲𝗹𝗶𝗮 𝗜𝗴𝗚 𝗮𝗻𝗱 𝗦𝗲𝗿𝗮𝗦𝗽𝗼𝘁® 𝗔𝗻𝘁𝗶-𝗕𝗼𝗿𝗿𝗲𝗹𝗶𝗮 𝗜𝗴𝗠 𝗮𝘀𝘀𝗮𝘆𝘀 at this year’s 𝗘𝘂𝗿𝗼𝗽𝗲𝗮𝗻 𝗧𝗶𝗰𝗸-𝗕𝗼𝗿𝗻𝗲 𝗗𝗶𝘀𝗲𝗮𝘀𝗲𝘀 (𝗘𝗧𝗕𝗗) 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 𝟮𝟬𝟮𝟲 in Cluj-Napoca.

Both products combine modern microarray technology with the convenience of established automated ELISA workflows, enabling simultaneous detection of antibodies against multiple Borrelia-specific antigens.